Microbiome in Transplant and Cellular Therapy Outcomes.

This observational study involves the collection from each time point (below): Blood samples, rectal swabs, frozen stool and bronchoalveolar lavage/ wash samples, processed and stored whole or as derivatives. To help us define the interaction between the microbiome and the outcomes of participants' transplant or cellular therapy. Clinical information and samples will be collected prospectively at the following timepoints for participants receiving Hematopoietic Stem Cell Transplantation (HSCT): - The day of patients transplant (Day 0); - Day 14 post-transplant; - Day of hospital discharge; and - Day 100 Participants who receive HSCT, are also invited to undergo the optional PET-scan at Day 14-18 post-transplant, and may be invited for a repeat scan if they are readmitted with GVHD. Patients who receive Chimeric Antigen Receptor (CAR) T/Natural Killer (NK) cellular therapy will have samples collected: - Day of infusion; - Day 14; - Day 30 and; - Day 100 post-infusion For patients that receive Solid Organ Transplantation, will have samples collected: - Prior to their scheduled transplant (Day of Listing on this study) - Day of transplant; - Day of hospital discharge post-transplant; - Day 21 post-transplant procedure; - Day 90 post-transplant; - 6 months post-transplant; and - 12 months post-transplant Participants may also be invited to donate samples if they are readmitted to hospital with an infection, or GVHD. Participants enrolled in this study will also have clinical information collected (if consented) during their collection timepoints and at Month 6 and 12 post-transplant/infusion check-ups. This may include disease indication, characteristics of Transplant and Cellular Therapy (TCT), incidence of acute toxicities and disease response, and incidence of longer-term complications, survival and episodes of Infection, GVHD and organ rejection. As well as the collection of information regarding other indirect complications of TCT, including but not limited to GVHD, infectious complications, immunological complications, duration of hospitalization and use of concurrent medications